Natural Neuroprotection: Exploring the Potential of Non-Psychoactive Cannabinoids

WHY IT MATTERS: Patients and caregivers exploring cannabinoid options for neurological conditions should understand that while the basic science is genuinely promising, the gap between preclinical findings and proven clinical treatments means these approaches are best pursued under informed medical guidance rather than based on headlines alone. CLINICAL OVERVIEW: The endocannabinoid system plays a fundamental role in regulating neuronal health, modulating inflammation, oxidative stress, and cell survival pathways that are central to neurodegenerative disease processes. Non-psychoactive cannabinoids such as CBD, CBG, and CBDV interact with receptors and signaling cascades throughout the central nervous system in ways that may slow or interrupt the progression of conditions like Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury sequelae.

Read More

Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML

WHY IT MATTERS: Patients managing anxiety who are curious about cannabis now have additional research supporting CBD-dominant products as a potentially effective option worth discussing with a knowledgeable clinician before making any changes to current treatment. CLINICAL OVERVIEW: CBD-dominant cannabis products are gaining clinical attention as a potential option for anxiety management, with research suggesting meaningful symptom relief in patients who use formulations where cannabidiol predominates over THC. The anxiolytic properties of CBD are thought to involve serotonergic signaling and modulation of the endocannabinoid system, particularly at CB1 receptors and 5-HT1A receptors, which distinguishes its mechanism from both benzodiazepines and SSRIs.

Read More

Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie

WHY IT MATTERS: Older adults considering cannabis for symptom management can point to this growing body of evidence when discussing cognitive safety concerns with their doctors. CLINICAL OVERVIEW: Emerging research is challenging long-held assumptions about cannabis use and cognitive aging, with data suggesting that older adults who use cannabis do not show accelerated cognitive decline or increased dementia risk compared to non-users. This is clinically relevant given that older adults are one of the fastest-growing segments of cannabis users, often turning to it for pain, sleep, and anxiety management.

Read More

Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC

WHY IT MATTERS: Patients with fatty liver disease or metabolic syndrome may eventually have access to cannabinoid-based therapies as an adjunct treatment option, but only after human clinical trials confirm the safety and efficacy signals seen in early research. CLINICAL OVERVIEW: Emerging preclinical research is examining how non-psychoactive cannabinoids, particularly CBD and CBG, may influence hepatic lipid metabolism and reduce fat accumulation in liver tissue. These compounds appear to interact with endocannabinoid receptors and metabolic pathways involved in fatty acid synthesis and inflammation, offering a potential therapeutic avenue for metabolic-associated steatotic liver disease.

Read More

Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease

WHY IT MATTERS: For the estimated 100 million Americans living with fatty liver disease and no approved medication options, this research opens a credible pharmaceutical pathway that could eventually produce a first-in-class treatment derived from cannabis compounds. CLINICAL OVERVIEW: Researchers in Israel have identified specific cannabinoid compounds that show meaningful activity against non-alcoholic fatty liver disease, a condition affecting hundreds of millions of people worldwide that currently has no approved pharmaceutical treatment. The compounds appear to work through mechanisms involving hepatic fat accumulation, inflammation, and fibrosis pathways, which aligns with what the endocannabinoid system is already known to regulate in metabolic and liver tissue.

Read More

Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults

WHY IT MATTERS: Older adults who use or are considering cannabis for conditions like pain, sleep, or anxiety can discuss this research with their physicians without the added concern that long-term use may increase their risk of cognitive decline or dementia. CLINICAL OVERVIEW: Emerging longitudinal research is adding to a growing body of evidence suggesting that lifetime cannabis use in older adults does not appear to accelerate cognitive decline or meaningfully elevate dementia risk. This is clinically significant because older adults represent one of the fastest-growing demographics of cannabis users, and concerns about neurological harm have historically discouraged both patient use and physician engagement.

Read More

Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

WHY IT MATTERS: Patients with chronic jaw and facial pain who have not found relief through standard treatments now have emerging clinical trial evidence supporting sublingual cannabis extracts as a potential therapeutic option worth discussing with their provider. CLINICAL OVERVIEW: Sublingual cannabis extract administration has demonstrated meaningful reductions in myofascial pain among patients with temporomandibular disorders, a condition historically resistant to conventional pharmacological approaches. The findings add to a growing body of evidence supporting cannabinoid-based interventions for chronic orofacial pain, where inflammation and central sensitization play significant roles.

Read More

Success Kid

Got prescribed cannabis for chronic pain. Actually read the dosing guidelines and didn’t immediately text everyone about it. Further Reading Cannabis NewsRecreational drugs triple the risk of stroke in young people, study...

Read More

Batman Slapping Robin

“Maybe we should try CBD for inflammation.” Batman: “That’s literally what the clinical evidence supports.” Robin gets slapped anyway because evidence-based medicine is apparently still controversial. Further Reading Cannabis NewsRecreational drugs triple...

Read More